Perinatal Outcomes with Tamsulosin Therapy for Symptomatic Urolithiasis

George Bailey, Lisa Vaughan, Carl Rose, Amy Krambeck

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose Medical expulsive therapy represents an effective adjunctive treatment for nonpregnant patients with symptomatic urolithiasis. Tamsulosin is classified by the FDA (Food and Drug Administration) as a category B medication. However, to our knowledge no published data exist for human pregnancy. We explored the safety and efficacy of tamsulosin therapy for symptomatic urolithiasis occurring during pregnancy. Materials and Methods We retrospectively identified patients treated with tamsulosin for stone disease during pregnancy at the Mayo Clinic during 2000 to 2014. This medical expulsive therapy cohort was matched 2:1 to pregnant women with symptomatic urolithiasis during pregnancy who did not receive medical expulsive therapy. Groups were compared using linear mixed models for continuous variables and exact conditional logistic regression models for nominal variables to take into account correlation due to matching. Results A total of 27 patients receiving medical expulsive therapy comprised the study cohort. Median duration of antepartum tamsulosin exposure was 3 days (range 1 to 110), occurring during the first, second and third trimester in 3 (11%), 11 (40.7%) and 18 (67%) patients, respectively. Mean gestational age at delivery was 38.1 weeks (SD 2.4) and 6 (22%) infants were born preterm. All infant birthweights were considered appropriate for gestational age, and no cases of spontaneous abortion, intrauterine demise or neonatal congenital anomalies were encountered. Comparison between the medical expulsive therapy and control groups demonstrated no significant differences in maternal or infant outcomes for any of the examined variables. Conclusions Tamsulosin medical expulsive therapy does not appear to be associated with adverse maternal or fetal outcomes and may be considered as adjunctive therapy for urolithiasis during pregnancy.

Original languageEnglish (US)
Pages (from-to)99-103
Number of pages5
JournalJournal of Urology
Volume195
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

tamsulosin
Urolithiasis
Pregnancy
Therapeutics
Gestational Age
Logistic Models
Mothers
Epidemiologic Effect Modifiers
Third Pregnancy Trimester
Second Pregnancy Trimester
Spontaneous Abortion
First Pregnancy Trimester
United States Food and Drug Administration

Keywords

  • drug therapy
  • pregnancy
  • tamsulosin
  • urolithiasis

ASJC Scopus subject areas

  • Medicine(all)
  • Urology

Cite this

Perinatal Outcomes with Tamsulosin Therapy for Symptomatic Urolithiasis. / Bailey, George; Vaughan, Lisa; Rose, Carl; Krambeck, Amy.

In: Journal of Urology, Vol. 195, No. 1, 01.01.2016, p. 99-103.

Research output: Contribution to journalArticle

Bailey, George ; Vaughan, Lisa ; Rose, Carl ; Krambeck, Amy. / Perinatal Outcomes with Tamsulosin Therapy for Symptomatic Urolithiasis. In: Journal of Urology. 2016 ; Vol. 195, No. 1. pp. 99-103.
@article{f14817b685e94076a0c9e53df60017fa,
title = "Perinatal Outcomes with Tamsulosin Therapy for Symptomatic Urolithiasis",
abstract = "Purpose Medical expulsive therapy represents an effective adjunctive treatment for nonpregnant patients with symptomatic urolithiasis. Tamsulosin is classified by the FDA (Food and Drug Administration) as a category B medication. However, to our knowledge no published data exist for human pregnancy. We explored the safety and efficacy of tamsulosin therapy for symptomatic urolithiasis occurring during pregnancy. Materials and Methods We retrospectively identified patients treated with tamsulosin for stone disease during pregnancy at the Mayo Clinic during 2000 to 2014. This medical expulsive therapy cohort was matched 2:1 to pregnant women with symptomatic urolithiasis during pregnancy who did not receive medical expulsive therapy. Groups were compared using linear mixed models for continuous variables and exact conditional logistic regression models for nominal variables to take into account correlation due to matching. Results A total of 27 patients receiving medical expulsive therapy comprised the study cohort. Median duration of antepartum tamsulosin exposure was 3 days (range 1 to 110), occurring during the first, second and third trimester in 3 (11{\%}), 11 (40.7{\%}) and 18 (67{\%}) patients, respectively. Mean gestational age at delivery was 38.1 weeks (SD 2.4) and 6 (22{\%}) infants were born preterm. All infant birthweights were considered appropriate for gestational age, and no cases of spontaneous abortion, intrauterine demise or neonatal congenital anomalies were encountered. Comparison between the medical expulsive therapy and control groups demonstrated no significant differences in maternal or infant outcomes for any of the examined variables. Conclusions Tamsulosin medical expulsive therapy does not appear to be associated with adverse maternal or fetal outcomes and may be considered as adjunctive therapy for urolithiasis during pregnancy.",
keywords = "drug therapy, pregnancy, tamsulosin, urolithiasis",
author = "George Bailey and Lisa Vaughan and Carl Rose and Amy Krambeck",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.juro.2015.06.097",
language = "English (US)",
volume = "195",
pages = "99--103",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Perinatal Outcomes with Tamsulosin Therapy for Symptomatic Urolithiasis

AU - Bailey, George

AU - Vaughan, Lisa

AU - Rose, Carl

AU - Krambeck, Amy

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Purpose Medical expulsive therapy represents an effective adjunctive treatment for nonpregnant patients with symptomatic urolithiasis. Tamsulosin is classified by the FDA (Food and Drug Administration) as a category B medication. However, to our knowledge no published data exist for human pregnancy. We explored the safety and efficacy of tamsulosin therapy for symptomatic urolithiasis occurring during pregnancy. Materials and Methods We retrospectively identified patients treated with tamsulosin for stone disease during pregnancy at the Mayo Clinic during 2000 to 2014. This medical expulsive therapy cohort was matched 2:1 to pregnant women with symptomatic urolithiasis during pregnancy who did not receive medical expulsive therapy. Groups were compared using linear mixed models for continuous variables and exact conditional logistic regression models for nominal variables to take into account correlation due to matching. Results A total of 27 patients receiving medical expulsive therapy comprised the study cohort. Median duration of antepartum tamsulosin exposure was 3 days (range 1 to 110), occurring during the first, second and third trimester in 3 (11%), 11 (40.7%) and 18 (67%) patients, respectively. Mean gestational age at delivery was 38.1 weeks (SD 2.4) and 6 (22%) infants were born preterm. All infant birthweights were considered appropriate for gestational age, and no cases of spontaneous abortion, intrauterine demise or neonatal congenital anomalies were encountered. Comparison between the medical expulsive therapy and control groups demonstrated no significant differences in maternal or infant outcomes for any of the examined variables. Conclusions Tamsulosin medical expulsive therapy does not appear to be associated with adverse maternal or fetal outcomes and may be considered as adjunctive therapy for urolithiasis during pregnancy.

AB - Purpose Medical expulsive therapy represents an effective adjunctive treatment for nonpregnant patients with symptomatic urolithiasis. Tamsulosin is classified by the FDA (Food and Drug Administration) as a category B medication. However, to our knowledge no published data exist for human pregnancy. We explored the safety and efficacy of tamsulosin therapy for symptomatic urolithiasis occurring during pregnancy. Materials and Methods We retrospectively identified patients treated with tamsulosin for stone disease during pregnancy at the Mayo Clinic during 2000 to 2014. This medical expulsive therapy cohort was matched 2:1 to pregnant women with symptomatic urolithiasis during pregnancy who did not receive medical expulsive therapy. Groups were compared using linear mixed models for continuous variables and exact conditional logistic regression models for nominal variables to take into account correlation due to matching. Results A total of 27 patients receiving medical expulsive therapy comprised the study cohort. Median duration of antepartum tamsulosin exposure was 3 days (range 1 to 110), occurring during the first, second and third trimester in 3 (11%), 11 (40.7%) and 18 (67%) patients, respectively. Mean gestational age at delivery was 38.1 weeks (SD 2.4) and 6 (22%) infants were born preterm. All infant birthweights were considered appropriate for gestational age, and no cases of spontaneous abortion, intrauterine demise or neonatal congenital anomalies were encountered. Comparison between the medical expulsive therapy and control groups demonstrated no significant differences in maternal or infant outcomes for any of the examined variables. Conclusions Tamsulosin medical expulsive therapy does not appear to be associated with adverse maternal or fetal outcomes and may be considered as adjunctive therapy for urolithiasis during pregnancy.

KW - drug therapy

KW - pregnancy

KW - tamsulosin

KW - urolithiasis

UR - http://www.scopus.com/inward/record.url?scp=84983134484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983134484&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.06.097

DO - 10.1016/j.juro.2015.06.097

M3 - Article

VL - 195

SP - 99

EP - 103

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -